NCI CIP-Net

NCI CIP-Net

@nci-cipnet.org

Official BlueSky account of the NCI Cancer Immunoprevention Network (CIP-Net). www.nci-cipnet.org

9 followers10 following71 posts

Pinned

The Cancer Immunoprevention Network, established by the National Cancer Institute, advances the understanding of fundamental immunoprevention mechanisms, drives the discovery of novel strategies, and supports the preclinical development and testing of new interventions. More info: nci-cipnet.org

nci-cipnet.orgCIP-Net

At today's #CIPNetSCMeeting, we thanked Dr. Haval Shirwan as he concluded his one-year term as rotating Chair. We are grateful for his inspiring leadership, dedication, and support of the network over the past year, and warmly welcome Dr. Shawn Demehri as the incoming Chair!

Co-Chair Dr. Alan Hutson shared updates on network activities, followed by presentations from Dr. John Clifford of National Cancer Institute, who introduced the PREVENT program.

And Dr. Yurong Song of Frederick National Laboratory for Cancer Research, who highlighted mouse model resources and the organoid platform available at the national laboratory.

Today, the #CIPNet Resource Sharing WG, co-chaired by Dr. Anjana Bhardwaj and Dr. Henry Withers, met to advance resource sharing across the network, including lab-validated SOPs and other shareable resources.The meeting also featured a presentation by Dr. Bonnie LaFleur of University of Arizona.

📢 Registration is open for the 4th Biennial Translational Advances in Cancer Prevention Agent Development (TACPAD) Virtual Meeting! 📅 September 28–30, 2026 💻 Virtual & free to attend Register: events.cancer.gov/cadrg/tacpad... #CancerPrevention #CancerResearch #TACPAD #CancerInterception #NCI

events.cancer.govcadrg-tacpad (Registration) | Events RegistrationRegistrationThank you for your interest in registering for the Translational Advances in Cancer Prevention Agent Development (TACPAD) – 4th Biennial Virtual Meeting. Please use the form below to regis...

Dr. Philip Castle, Director of the NCI Division of Cancer Prevention (DCP), delivered an insightful and inspiring featured seminar on “No Cancer” Research, challenging us to think about what success in cancer research ultimately looks like: preventing cancer before it ever develops.

View full thread

The paper strongly echoed a central message of Dr. Castle’s seminar: if we all prefer “no cancer” to treating cancer after it develops, how do we build a research, healthcare, and societal system that truly prioritizes prevention?

The seminar clearly resonated with the audience. The presentation was followed by a lively discussion and many thoughtful questions: a reflection of how motivated the #CIPNet community is to rethink cancer research: What if the best cancer outcome is simply “No Cancer”?

Dr. Philip Castle, Director of the NCI Division of Cancer Prevention (DCP), delivered an insightful and inspiring featured seminar on “No Cancer” Research, challenging us to think about what success in cancer research ultimately looks like: preventing cancer before it ever develops.

View full thread

Its successes are often invisible, benefits may take years to emerge, financial incentives are not always aligned, and prevention is frequently held to a higher economic standard than treatment.

Fineberg also outlines strategies for overcoming these barriers through better incentives, policy, communication, and systems that make prevention easier to adopt.

Dr. Philip Castle, Director of the NCI Division of Cancer Prevention (DCP), delivered an insightful and inspiring featured seminar on “No Cancer” Research, challenging us to think about what success in cancer research ultimately looks like: preventing cancer before it ever develops.

View full thread

To conclude his seminar, Dr. Castle recommended Harvey V. Fineberg’s thought-provoking paper, “The Paradox of Disease Prevention: Celebrated in Principle, Resisted in Practice.”

The paper explores a fundamental paradox of prevention: although virtually everyone values preventing disease, prevention can be remarkably difficult to implement and sustain in practice.

Dr. Philip Castle, Director of the NCI Division of Cancer Prevention (DCP), delivered an insightful and inspiring featured seminar on “No Cancer” Research, challenging us to think about what success in cancer research ultimately looks like: preventing cancer before it ever develops.

View full thread

Under Dr. Castle's leadership, DCP continues to advance research across its major areas, including preventive agents, screening and early detection, and symptom science and prevention/management, with numerous programs and clinical research initiatives steadily moving the field forward.

Dr. Castle also recognized Roswell Park Comprehensive Cancer Center for its strong commitment to clinical trials and its continued support of DCP's cancer prevention research.

Dr. Philip Castle, Director of the NCI Division of Cancer Prevention (DCP), delivered an insightful and inspiring featured seminar on “No Cancer” Research, challenging us to think about what success in cancer research ultimately looks like: preventing cancer before it ever develops.

View full thread

Dr. Castle discussed both the enormous potential and the unique challenges of cancer prevention. Prevention can be scientifically complex, require long-term investment and follow-up, and may not always provide the immediate financial incentives needed for the private sector to lead.

Yet it is far too important to patients, families, and the communities we serve to be overlooked. This is why sustained public investment and a coordinated national effort are essential.

Dr. Philip Castle, Director of the NCI Division of Cancer Prevention (DCP), delivered an insightful and inspiring featured seminar on “No Cancer” Research, challenging us to think about what success in cancer research ultimately looks like: preventing cancer before it ever develops.

An onsite poll at the beginning of the seminar said it all: everyone wanted cancer to be prevented; no one chose to be diagnosed with cancer and then treated. It was a simple but powerful reminder of why prevention matters.

Dr. Alan Hutson of Roswell Park Comprehensive Cancer Center presented updates on the work of the CIP-Net Data and Resource Coordinating Center (DRCC). As the host of this year’s Annual Meeting, he also shared some fun facts about Buffalo that many attendees may not have known!

View full thread

The team has also developed podcast and newsletter series to expand community engagement and outreach. Beyond these efforts, the DRCC provides analytical support to CIP-Net investigators and facilitates collaborations and resource sharing across the network.

Through these initiatives, the DRCC continues to bring the #CIPNet consortium together as a more connected, collaborative, and unified effort to advance cancer immunoprevention.

Dr. Alan Hutson of Roswell Park Comprehensive Cancer Center presented updates on the work of the CIP-Net Data and Resource Coordinating Center (DRCC). As the host of this year’s Annual Meeting, he also shared some fun facts about Buffalo that many attendees may not have known!

The DRCC has proactively launched a range of initiatives to strengthen and connect the CIP-Net community:from harnessing AI tools to build automatically populated publication and AI webinar catalogs, to curating useful resources for members, particularly ESIs.

Dr. Nicholas Arpaia, Chair of the Community Engagement Working Group, Dr. Anjana Bhardwaj and Dr. Henry Withers, Chair and Co-Chair of the Resource Sharing Working Group, shared updates on the progress and activities of their respective WGs.

Both groups have played an important role in strengthening CIP-Net as a collaborative network: connecting members, fostering new collaborations, engaging with the broader community, and promoting resource sharing across the consortium.

These efforts reflect a core goal of #CIPNet: bringing investigators together to accelerate progress in cancer immunoprevention.

Dr. Phillip Castle, Director of the NCI Division of Cancer Prevention, delivered opening remarks to kick off Day 2 of the hashtag#CIPNet Annual Meeting, setting the stage for discussions on advancing cancer immunoprevention.

At the #CIPNet Annual Meeting, the panel “Identifying Risks and Benefits in Cancer Immunoprevention from the Patient Perspective” brought patient advocates and researchers together to discuss how patient experiences can shape research priorities, clinical trial design, and communication.

View full thread

The discussion also explored risk-benefit decisions, quality of life, financial burden, and access to understandable information so patients can make informed choices about prevention and treatment.

A powerful takeaway: patient perspectives need to be incorporated throughout cancer immunoprevention research:from risk communication and trial design to toxicity, quality of life, and dissemination of results.

At the #CIPNet Annual Meeting, the panel “Identifying Risks and Benefits in Cancer Immunoprevention from the Patient Perspective” brought patient advocates and researchers together to discuss how patient experiences can shape research priorities, clinical trial design, and communication.

Moderated by Drs. Robert Shoemaker and Kevin Howcroft of NCI, the panel featured patient advocates Nicole Black, Eric Blackburn, and Dr. Bodour Salhia, alongside CIP-Net researchers Dr. Isabelle Bedrosian of UT MD Anderson and Dr. Nicholas Arpaia of Columbia University.

Patient advocates shared their cancer journeys and emphasized what prevention can mean to patients and their families, particularly for those with inherited cancer risk: the possibility of identifying risk earlier, preventing cancer before it develops, and potentially avoiding toxic treatments.

The CIP-Net Annual Meeting kicked off today at Roswell Park Comprehensive Cancer Center, bringing together 40+ attendees from institutions across the nation! CIP-Net Steering Committee Co-Chair and DRCC Contact PI Dr. Alan Hutson officially opened the meeting.

View full thread

Dr. Gallahan highlighted the importance of cancer immunoprevention, NCI’s commitment to advancing this emerging field, and the need for the broader cancer research community to contribute to this important effort.

Dr. Johnson welcomed attendees to Roswell Park, sharing its history and mission and reaffirming the institution’s longstanding commitment to ending cancer as one of the nation’s oldest cancer centers.

The CIP-Net Annual Meeting kicked off today at Roswell Park Comprehensive Cancer Center, bringing together 40+ attendees from institutions across the nation! CIP-Net Steering Committee Co-Chair and DRCC Contact PI Dr. Alan Hutson officially opened the meeting.

Dr. Dan Gallahan, Director of the Division of Cancer Biology at National Cancer Institute (NCI), and Dr. Candace Johnson, PhD, President and CEO of Roswell Park Comprehensive Cancer Center, delivered welcoming remarks.

What is cancer immunoprevention and how does it work? The #CIPNet Community Engagement Working Group created this infographic to make the science of cancer immunoprevention more accessible to everyone. 📥 Download it, share it, and help us spread the knowledge! #CancerImmunotherapy #CancerPrevention

This is why we have invested so much time and effort in promoting resource sharing within our network—not only to reduce waste, but also to share resources, including antibodies, together with the collective validation experience and knowledge of our research community.

At today’s #CIPNetSCMeeting, SC co-chair Dr. Alan Hutson provided an overview of network activities. Dr. Anirban Maitra introduced the NCI TBEL Consortium and highlighted its research progress in pancreatic cancer. Dr. Shawn Demehri shared progress from his UH3 project.

Worth revisiting: a 2020 perspective published in Cancer Prevention Research, exploring the challenges and potential opportunities for immune checkpoint inhibitors in cancer immunoprevention. The concepts remain highly relevant to #CIPNet’s mission today. 🔗 doi.org/10.1158/1940...

doi.orgCancer Immunoprevention: Challenges and Potential Opportunities for Use of Immune Checkpoint InhibitorsAbstract. Cancer immunoprevention is achieved through promoting antitumor immune surveillance to block tumor formation and progression. Following the success of prophylactic vaccines against human pap...

What if bacteria could be programmed to find tumors and deliver cancer therapies directly where they're needed? A new Nature Cancer Perspective by Noah Chen, Zaofeng Yang, and Nicholas Arpaia explores the promise of engineered bacteria as living therapeutics: rdcu.be/fmtyo

rdcu.beBacterial engineering for cancer therapyNature Cancer - In this Perspective, Arpaia and colleagues provide an overview of bacteria-based cancer therapies, discussing the potential of engineered bacteria as living drug delivery systems as...